Canada Markets closed

Akero Therapeutics, Inc. (0K4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
44.40-0.20 (-0.45%)
At close: 08:03AM CET
Full screen
Previous Close44.60
Open44.40
Bid45.20 x N/A
Ask45.40 x N/A
Day's Range44.40 - 44.40
52 Week Range7.40 - 53.50
Volume18
Avg. Volume21
Market Cap1.549B
Beta (5Y Monthly)-1.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. “Akero is thrilled to welcome Patrick to the team, especially following last year’s HARMONY study results, which further demonstrate EFX’s potential to treat

  • GlobeNewswire

    Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA. A live webcast of the Company presentation will be available through the investor r

  • GlobeNewswire

    Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

    Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023 Results of the cohort D expansion to evaluate EFX in combination with GLP-1 therapy in patients with pre-cirrhotic NASH expected in second quarter of 2023 Following designation of EFX as a Breakthrough Therapy, a meeting has been scheduled for March 2023 with FDA to review results of the Phase 2b HARMONY study and to obtain feedback on a proposed Phase 3 clinical program SOUTH SAN